|As first reported by the Ottawa Citizen — "A team of University of Ottawa researchers has solved the mystery of how our bodies adapt to low-oxygen environments, raising the prospect that life-threatening conditions such as cancer, stroke and heart disease could someday be successfully treated using a simple, antibiotic-like drug."||
Dr. Stephen Lee, a professor in the Department of Cellular and Molecular Medicine at University of Ottawa.
The research for this discovery was performed in the HypOxystation (a low-oxygen workstation / incubator) frοm HypOxygen. The HypOxystation allows researchers to precisely control oxygen levels from 0.1% to 20% in 0.1% increments as well as controlling CO2, temperature and humidity throughout the course of their experiments to accurately model in situ environments in vitro.
Dr. Stephen Lee at the University of Ottawa, used the HypOxystation to mimic the effect of high altitude to study how cells function in low-oxygen environments.
HypOxygen was founded to provide technology with the level of precision and accuracy necessary for scientific study and research. We specialize in hypoxic chambers (or low oxygen incubators) for scientists focusing on cell research applications requiring precise atmospheric conditions that can be accurately controlled. Unlike a commonly used CO2 incubator, our hypoxia workstations can achieve these precise conditions.
Our 30 years of experience with atmosphere controlled hypoxic workstations has provided the foundation for the development of superior technological advances in programmable gas controlled workstations. The ability to replicate accurate and specific gas levels gives scientists the tools to perform research in conditions comparable with those found in vivo. Our hypoxia chamber is the most recent addition to our complete line of atmospheric workstations.
HypOxygen is resolute in its mission to forge ahead with state of the art hypoxic workstation technology that leads the way in advancing research and innovation, while providing continued reliability for optimum results.
I my HypOxystation
We have used two HypOxystations for about two years now to investigate the role of hypoxia in tumor microenvironments. They are running constantly without any problems. With the results being generated, and the demand for their use, we have now purchased a third instrument.
Dr. Bradley Wouters
Ontario Cancer Institute, Canada“”
- Amaya - Genome-wide identification of hypoxia-inducible factor binding sites
- Castellano - Jnl of Molec & Cell Cardiol 2011
- Phillips - Importance of Oxygen Control
- Horemans - Helicobacter 2011
- Pescador - Hypoxia Promotes Glycogen Accumulation 2010
- Nagelkerke - Cancer 2011
- Wennemers - Radiotherapy and Oncology 2011
- Cerna - Comparison of Radiosensitizing Effects of PARP Inhibitors
- Cancer Research Case Study